Latest metronidazole Stories
In an analysis of the results of interventions to eradicate the bacterium Helicobacter pylori (a risk factor for gastric cancer) in seven diverse community populations in Latin America, researchers found that geographic site, demographic factors, adherence to initial therapy and infection recurrence may be as important as the choice of antibiotic regimen in H pylori eradication interventions.
Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or MetronidazoleTokyo/Osaka, Aug 31, 2012 - (JCN Newswire) - Takeda Pharmaceutical
EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI. The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in...
SAN DIEGO, May 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID(TM) (fidaxomicin), an investigational antibiotic for the treatment of Clostridium difficile Infection (CDI), at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The analysis showed that above...
SAN DIEGO, May 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
- An interdisciplinary study of social injustice.